Stryker Co. (NYSE:SYK) is Parkman Healthcare Partners LLC's 5th Largest Position

Parkman Healthcare Partners LLC lifted its stake in shares of Stryker Co. (NYSE:SYK - Free Report) by 177.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 77,717 shares of the medical technology company's stock after buying an additional 49,717 shares during the quarter. Stryker comprises about 3.7% of Parkman Healthcare Partners LLC's holdings, making the stock its 5th biggest holding. Parkman Healthcare Partners LLC's holdings in Stryker were worth $27,982,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of SYK. Mufg Securities Americas Inc. purchased a new stake in Stryker in the 4th quarter valued at $1,824,000. Nia Impact Advisors LLC raised its position in Stryker by 0.5% in the 4th quarter. Nia Impact Advisors LLC now owns 9,523 shares of the medical technology company's stock valued at $3,429,000 after purchasing an additional 43 shares during the last quarter. Nomura Holdings Inc. raised its position in Stryker by 220.2% in the 4th quarter. Nomura Holdings Inc. now owns 15,925 shares of the medical technology company's stock valued at $5,734,000 after purchasing an additional 10,951 shares during the last quarter. Nearwater Capital Markets Ltd purchased a new stake in Stryker in the 4th quarter valued at $36,304,000. Finally, NorthRock Partners LLC raised its position in Stryker by 375.4% in the 4th quarter. NorthRock Partners LLC now owns 15,578 shares of the medical technology company's stock valued at $5,609,000 after purchasing an additional 12,301 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on SYK. Needham & Company LLC reissued a "buy" rating and issued a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a research report on Monday, May 5th. Finally, Truist Financial boosted their price objective on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a research report on Monday, May 5th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $427.05.

Stryker Stock Down 0.0%

SYK opened at $387.92 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The firm has a 50 day moving average price of $365.43 and a 200 day moving average price of $374.82. The company has a market cap of $148.06 billion, a PE ratio of 49.99, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter last year, the company earned $2.50 earnings per share. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. Sell-side analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's payout ratio is currently 45.41%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares of the company's stock, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company's stock, valued at $5,705,827.65. The trade was a 14.16% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.